Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NSC-659687)

Primary Language	English
Journal Section	Articles
Authors	G. Atassi This is me A. Pierre This is me N. Guilbaud This is me L. Kraus-berthier This is me D. Saint-dizier This is me E. Bisagni This is me
Publication Date	March 30, 2015
Published in Issue	Year 1995 Volume: 11 Issue: 1-2

Cite

APA	Atassi, G., Pierre, A., Guilbaud, N., Kraus-berthier, L., et al. (2015). Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NSC-659687). Marmara Pharmaceutical Journal, 11(1-2), 141-150. https://doi.org/10.12991/mpj.61492
AMA	Atassi G, Pierre A, Guilbaud N, Kraus-berthier L, Saint-dizier D, Bisagni E. Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NSC-659687). J Res Pharm. April 2015;11(1-2):141-150. doi:10.12991/mpj.61492
Chicago	Atassi, G., A. Pierre, N. Guilbaud, L. Kraus-berthier, D. Saint-dizier, and E. Bisagni. “Preclinical Antitumor Activity of a Novel Olivacine Derivative: S 16020-2 (NSC-659687)”. Marmara Pharmaceutical Journal 11, no. 1-2 (April 2015): 141-50. https://doi.org/10.12991/mpj.61492.
EndNote	Atassi G, Pierre A, Guilbaud N, Kraus-berthier L, Saint-dizier D, Bisagni E (April 1, 2015) Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NSC-659687). Marmara Pharmaceutical Journal 11 1-2 141–150.
IEEE	G. Atassi, A. Pierre, N. Guilbaud, L. Kraus-berthier, D. Saint-dizier, and E. Bisagni, “Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NSC-659687)”, J Res Pharm, vol. 11, no. 1-2, pp. 141–150, 2015, doi: 10.12991/mpj.61492.
ISNAD	Atassi, G. et al. “Preclinical Antitumor Activity of a Novel Olivacine Derivative: S 16020-2 (NSC-659687)”. Marmara Pharmaceutical Journal 11/1-2 (April 2015), 141-150. https://doi.org/10.12991/mpj.61492.
JAMA	Atassi G, Pierre A, Guilbaud N, Kraus-berthier L, Saint-dizier D, Bisagni E. Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NSC-659687). J Res Pharm. 2015;11:141–150.
MLA	Atassi, G. et al. “Preclinical Antitumor Activity of a Novel Olivacine Derivative: S 16020-2 (NSC-659687)”. Marmara Pharmaceutical Journal, vol. 11, no. 1-2, 2015, pp. 141-50, doi:10.12991/mpj.61492.
Vancouver	Atassi G, Pierre A, Guilbaud N, Kraus-berthier L, Saint-dizier D, Bisagni E. Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NSC-659687). J Res Pharm. 2015;11(1-2):141-50.